Scancell Ltd.
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Public, Subsidiary
- Established
- 1996-01-01
- Employees
- 11
- Market Cap
- -
Modi-1 in Breast, Head and Neck, Ovarian, or Renal Cancer
Phase 1
Recruiting
- Conditions
- Triple Negative Breast CancerRenal Cell CancerSquamous Cell Carcinoma of the Head and NeckHigh Grade Ovarian Serous Adenocarcinoma
- Interventions
- Biological: Modi-1/Modi-1vDevice: MicronJet600β’ microneedle device (NanoPass)Biological: Pembrolizumab
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2022-11-21
- Lead Sponsor
- Scancell Ltd
- Target Recruit Count
- 144
- Registration Number
- NCT05329532
- Locations
- π¬π§
Brighton and Sussex University Hospital, Brighton, Default, United Kingdom
π¬π§Velindre Cancer Centre, Cardiff, Default, United Kingdom
π¬π§Edinburgh Cancer Centre (NHS Lothian), Edinburgh, Default, United Kingdom
A First Time in Human Phase 1 Open-Label Study of the COVIDITY Vaccine Administered by Needle-free Injection
Phase 1
Active, not recruiting
- Conditions
- COVID-19
- Interventions
- Biological: COVIDITY (SCOV1 and SCOV2) administered via needle-free intradermal injectionBiological: COVIDITY (SCOV1 and SCOV2) administered via needle-free intramuscular injectionBiological: COVIDITY (SCOV2 only) administered via needle-free intradermal injection to vaccine naive and/or previously vaccinated participantsBiological: COVIDITY (SCOV2 only) administered via needle-free intramuscular injection to vaccine naive and/or previously vaccinated participantsBiological: COVIDITY (SCOV2 only) administered via needle-free intradermal injection to previously infected participantsBiological: COVIDITY (SCOV2 only) administered via needle-free intramuscular injection to previously infected participants
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2022-11-25
- Lead Sponsor
- Scancell Ltd
- Target Recruit Count
- 80
- Registration Number
- NCT05047445
- Locations
- πΏπ¦
University of Cape Town Lung Institute, Centre for TB Research Innovation, Cape Town, Western Cape, South Africa
SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
Phase 2
Recruiting
- Conditions
- Malignant MelanomaMelanoma (Skin)Melanoma Stage IVMelanoma Stage III
- Interventions
- Biological: SCIB1 or iSCIB1+ DNA vaccine
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Scancell Ltd
- Target Recruit Count
- 173
- Registration Number
- NCT04079166
- Locations
- π¬π§
Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
π¬π§Velindre University NHS Trust, Cardiff, United Kingdom
π¬π§The Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Study of a DNA Immunotherapy to Treat Melanoma
Phase 1
Terminated
- Conditions
- Malignant Melanoma
- Interventions
- Biological: SCIB1
- First Posted Date
- 2010-06-07
- Last Posted Date
- 2017-08-21
- Lead Sponsor
- Scancell Ltd
- Target Recruit Count
- 35
- Registration Number
- NCT01138410
- Locations
- π¬π§
Department of Medical Oncology, The Royal Surrey County Hospital, Guildford, Surrey, United Kingdom
π¬π§St James' Institute of Oncology, Leeds, United Kingdom
π¬π§Christie Hospital, Manchester, United Kingdom
Β© Copyright 2025. All Rights Reserved by MedPath